Full Press Release Details
Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress
resubmission anticipated in second half of 2024
$75 million underwritten offering in May, extending expected cash runway into 2026
May 15, 2024 - Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2024 and recent
are grateful to our existing as well as new investors who have demonstrated their support through the recent financing, which has extended
our cash runway into 2026, well beyond anticipated regulatory milestones," said Vish Seshadri, Chief Executive Officer of Abeona.
"We now remain focused on working with the FDA to address the CMC deficiencies noted in the CRL and making the BLA resubmission
to bring pz-cel to RDEB patients as soon as possible."
Quarter and Recent Progress
| On May 7, 2024, Abeona closed a $75 million underwritten securities offering with participation from both new and existing investors. | |
| In January 2024, Abeona entered into a $50 million credit facility and received the first tranche of $20 million. |
| In April 2024, Abeona received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company's Biologics License Application (BLA) for prademagene zamikeracel ( pz-cel) for recessive dystrophic epidermolysis bullosa (RDEB), based on the need for additional Chemistry Manufacturing and Controls (CMC) information. In the CRL, the FDA noted that certain additional information needed to satisfy CMC requirements must be resolved before the application can be approved. The information needed to satisfy the CMC requests in the CRL pertains to validation requirements for certain manufacturing and release testing methods. The CRL did not identify any deficiencies related to the clinical efficacy or clinical safety data in the BLA, and the FDA did not request any new clinical trials or clinical data to support the approval of pz-cel. The Company anticipates completing the BLA resubmission in the second half of 2024. | |
| New pz-cel data will be presented at upcoming medical meetings. At the Society for Investigative Dermatology (SID) Annual Meeting, being held on May 15-18, 2024, new long-term safety data with up to 11 years of follow-up has been accepted as a late-breaking presentation. |
commercial launch preparations for pz-cel
Quarter Financial Results and Cash Runway Guidance
cash equivalents, restricted cash and short-term investments totaled $62.7 million as of March 31, 2024, compared to $52.6 million as
of December 31, 2023. Net cash used in operating activities was $14.5 million for the three months ended March 31, 2024.
estimates that its current cash and cash equivalents, restricted cash and short-term investments, as well as the credit facility, combined
with the net proceeds from the underwritten securities offering, are sufficient resources to fund operations into 2026, before accounting
for any potential revenue from commercial sales of pz-cel, if approved, or proceeds from the sale of a Priority Review Voucher or PRV,
if awarded by the FDA.
and development expenses for the three months ended March 31, 2024 were $7.2 million, compared to $8.0 million for the same period of
2023. General and administrative expenses were $7.1 million for the three months ended March 31, 2024, compared to $4.0 million for the
same period of 2023. Net loss was $31.6 million for the first quarter of 2024, or $1.16 loss per common share, including a change in
the fair value of warrant liabilities due to remeasurement of the Company's issued stock purchase warrants. Net loss in the first
quarter of 2023 was $9.1 million, or $0.54 loss per common share.
Company will host a conference call and webcast on Wednesday, May 15, 2024, at 8:30 a.m. ET, to discuss the first quarter results. To
access the call, dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and Entry Code: 496484 five minutes prior to the
start of the call. A live, listen-only webcast and archived replay of the call can be accessed on the Investors & Media section of
Abeona's website at https://investors.abeonatherapeutics.com/events. The archived webcast replay will be available for 30
days following the call.
Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene
zamikeracel (pz-cel) is Abeona's investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development
for recessive dystrophic epidermolysis bullosa. The Company's fully integrated cell and gene therapy cGMP manufacturing facility
served as the manufacturing site for pz-cel used in its Phase 3 VIITAL trial, and is capable of supporting commercial production
of pz-cel upon FDA approval. The Company's development portfolio also features AAV-based gene therapies for ophthalmic diseases
with high unmet medical need. Abeona's novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a
variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted
to identify forward-looking statements by such terminology as "may," "will," "believe," "anticipate,"
"expect," "intend," "potential," and similar words and expressions (as well as other words or expressions
referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual
results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous
risks and uncertainties, including but not limited to, the timing and results of ongoing testing and other corrective actions being performed
in response to the FDA's identified deficiencies, which could delay the Company's BLA resubmission; the timing and outcome
of the FDA's review of our resubmission; the FDA's grant of a Priority Review Voucher upon approval; continued interest in
our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with the FDA or other regulatory
agencies, including those relating to preclinical programs; the ability to achieve or obtain necessary regulatory approvals; the impact
of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other
risks disclosed in the Company's most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities
and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events
or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise,
except as required by the federal securities laws.
Investor Relations and Corporate Communications
THERAPEUTICS INC. AND SUBSIDIARIES
Consolidated Statements of Operations and Comprehensive Loss
thousands, except share and per share amounts)
| For the three months ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Revenues: | ||||||||
| License and other revenues | $ | - | $ | - | ||||
| Expenses: | ||||||||
| Research and development | 7,207 | 8,041 | ||||||
| General and administrative | 7,123 | 3,997 | ||||||
| Total expenses | 14,330 | 12,038 | ||||||
| Loss from operations | (14,330 | ) | (12,038 | ) | ||||
| Interest income | 843 | 364 | ||||||
| Interest expense | (952 | ) | (101 | ) | ||||
| Change in fair value of warrant and derivative liabilities | (17,301 | ) | 2,265 | |||||
| Other income | 162 | 403 | ||||||
| Net loss | $ | (31,578 | ) | $ | (9,107 | ) | ||
| Basic and diluted loss per common share | $ | (1.16 | ) | $ | (0.54 | ) | ||
| Weighted average number of common shares outstanding - basic and diluted | 27,315,537 | 16,904,024 | ||||||
| Other comprehensive income (loss): | ||||||||
| Change in unrealized (losses) gains related to available-for-sale debt securities | (118 | ) | 64 | |||||
| Comprehensive loss | $ | (31,696 | ) | $ | (9,043 | ) |
THERAPEUTICS INC. AND SUBSIDIARIES
Consolidated Balance Sheets
thousands, except share and per share amounts)
| March 31, 2024 | December 31, 2023 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 17,558 | $ | 14,473 | ||||
| Short-term investments | 44,786 | 37,753 | ||||||
| Restricted cash | 338 | 338 | ||||||
| Other receivables | 2,232 | 2,444 | ||||||
| Prepaid expenses and other current assets | 1,811 | 729 | ||||||
| Total current assets | 66,725 | 55,737 | ||||||
| Property and equipment, net | 3,767 | 3,533 | ||||||
| Operating lease right-of-use assets | 4,222 | 4,455 | ||||||
| Other assets | 114 | 277 | ||||||
| Total assets | $ | 74,828 | $ | 64,002 | ||||
| LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,362 | $ | 1,858 | ||||
| Accrued expenses | 2,791 | 5,985 | ||||||
| Current portion of operating lease liability | 1,044 | 998 | ||||||
| Current portion payable to licensor | 4,691 | 4,580 | ||||||
| Other current liabilities | 1 | 1 | ||||||
| Total current liabilities | 11,889 | 13,422 | ||||||
| Long-term operating lease liabilities | 4,046 | 4,402 | ||||||
| Long-term debt | 18,079 | - | ||||||
| Derivative liabilities | 1,005 | - | ||||||
| Warrant liabilities | 48,690 | 31,352 | ||||||
| Total liabilities | 83,709 | 49,176 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' (deficit) equity: | ||||||||
| Preferred stock - $0.01 par value; authorized 2,000,000 shares; No shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | - | - | ||||||
| Common stock - $0.01 par value; authorized 200,000,000 shares; 27,550,693 and 26,523,878 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 276 | 265 | ||||||
| Additional paid-in capital | 772,129 | 764,151 | ||||||
| Accumulated deficit | (781,102 | ) | (749,524 | ) | ||||
| Accumulated other comprehensive loss | (184 | ) | (66 | ) | ||||
| Total stockholders' (deficit) equity | (8,881 | ) | 14,826 | |||||
| Total liabilities and stockholders' equity | $ | 74,828 | $ | 64,002 |